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Neither the biology nor the modes of transmission of
antibiotic-resistant bacteria differ from country to country.
It could, therefore, be assumed that measures to prevent the
transmission of such pathogens between patients would be
more or less uniform throughout the world. However, this
is not the case. As reported by Hansen and colleagues,
there is a wide variation in the infection control measures
taken to prevent the spread of methicillin-resistant
Staphylococcus aureus (MRSA) even between the coun-
tries of Europe [1]. These authors carried out a survey of
ten national networks from countries located in northern,
western and eastern Europe in which they assessed infec-
tion control measures in 526 intensive care units (ICUs)
and 223 surgical departments. Their findings reveal, among
others, variations in the availability of alcohol-based hand
sanitizer at the bedside as well as in the use of routine
surveillance cultures among contact patients. There was
also a marked variation in the use of decolonization
measures, such as nasal mupirocin and antiseptic washing,
among both the intensive care units and surgical
departments.
The reasons for the observed differences are not known.
It may be speculated that differences in the epidemiology
of MRSA together with differences in available resources
between countries may have an impact on the implemen-
tation of infection control measures aimed at preventing the
spread of MRSA. However, these differences should not
detract from the results of several studies showing that an
increased effort and an improved compliance with
infection control measures may positively impact the
incidence of MRSA [2, 3]. It can also be argued that
infection control measures to prevent the spread of MRSA
are relatively simple, inexpensive and easy to teach. Con-
sequently, it should be possible to implement these mea-
sures easily in hospitals with a higher prevalence of
MRSA. The study by Hansen et al. provides further support
for the comprehensive implementation of prevention
measures likely to have a positive impact on MRSA
prevalence. Therefore, an international consensus on
infection control measures should be the goal and would be
in the common interest of most countries.
This point is further illustrated by the report of Routsi
and colleagues describing a high rate of bacteremia caused
by carbapenem-resistant Acinetobacter baumannii in a
Greek ICU [4]. In this study, the authors report that 11.4%
of ICU patients with a stay of more than 48 h developed
bacteremia with A. baumannii, with almost a third of these
bacteremia episodes being caused by carbapenem-resistant
A. baumannii. These rates are very high and disturbing—
also because most of the episodes of carbapenem-resistant
A. baumannii bacteremia were likely caused by contact
transmission. In order to combat this emerging problem of
very broad resistance in A. baumannii, it is paramount to
focus on appropriate infection control measures. As the
problem of carbapenem-resistant A. baumannii affects
many countries, an international consensus is also required
on infection control measures against this pathogen.
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